natgillin/translations-raw huggingface dataset:
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least three different CC chemokines selected from the group consisting of CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL14/HCC-1, CCL15/HCC-2, CCL18/PARC, and CCL23/MPIF-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje tri CCkemokina odabrana iz skupine koja se sastoji od CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL14/HCC-1, CCL15/HCC-2, CCL18/PARC i CCL23/MPIF-1.
The monoclonal antibody or antigen binding fragment of claim 1, which binds to at least one determinant of CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL14/HCC-1, CCL15/HCC-2, CCL18/PARC, and CCL23/MPIF-1 which determinant is located between the CC residues of said CC-chemokine and the last C residue of said chemokine. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje jednu determinantu CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP- 1β, CCL5/RANTES, CCL14/HCC-1, CCL15/HCC-2, CCL18/PARC, i CCL23/MPIF-1 koja se nalazi između CC ostataka navedenih CC-kemokina i posljednjeg C ostatka navedenog kemokina.
The monoclonal antibody or antigen binding fragment of claim 1, which binds to at least one determinant within CC receptor binding residues of a CC chemokine. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje jednu determinantu unutar veznog ostatka CC receptora CC kemokina.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which is produced by hybridoma cell line 3C12F, 7D1G, 7D12A, 18V4F or 18P7E or which competitively blocks binding of an antibody produced by hybridoma cell line 3C12F, 7D1G, 7D12A, 18V4F or 18P7E, wherein 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da je proizveden od hibridne stanične linije, 3C12F, 7D1G, 7D12A, 18V4F ili 18P7E ili koji kompetitivno blokira vezanje protutijela kojeg proizvodi hibridna stanična linija 3C12F, 7D1G, 7D12A, 18V4F ili 18P7E, pri čemu je
said hybridoma cell line 7D1G was deposited on August 12,2010 at the ATCC under the accession number PTA-11257, 
navedena hibridna stanična linija 7D1G je pohranjena 12. kolovoza 2010. u ATCC pod pristupnim brojem PTA-11257,
said hybridoma cell line 7D12A was deposited on August 12, 2010 at the ATCC under the accession number PTA-11259, 
navedena hibridna stanična linija 7D12A pohranjena 12. kolovoza 2010. u ATCC pod pristupnim brojem PTA-11259,
said hybridoma cell line 18V4F was deposited on August 12, 2010 at the ATCC under the accession number PTA-11260, and 
navedena hibridna stanična linija 18V4F pohranjena 12. kolovoza 2010. u ATCC pod pristupnim brojem PTA-11260, i
said hybridoma cell line 18P7E was deposited on August 12,2010 at the ATCC under the accession number PTA-11258. 
navedena hibridna stanična linija 18P7E je pohranjena 12. kolovoza 2010. u ATCC pod pristupnim brojem PTA-11258.
The monoclonal antibody or antigen binding fragment thereof of claim 1 which binds to at least five CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL15/HCC-2, and CCL23/MPIF-1, and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje pet CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL15/HCC-2, i CCL23/MPIF-1, i koji se ne veže na CCL2/MCP-1.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least five CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL15/HCC-2, and CCL23/MPIF-1, and which does not bind to CCL2/MCP-1, comprising heavy and light chain CDR sequence combinations (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) selected from the group consisting of SEQ ID NO: 3/4/5/8/9/10 and 53/54/55/58/59/60, or which competes for binding to at least five CC chemokines selected from CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL15/HCC-2, and CCL23/MPIF-1, with an antibody or antigen binding fragment comprising heavy and light chain CDR sequence combinations selected from the group consisting of SEQ ID NO: 3/4/5/8/9/10 and 53/54/55/58/59/60. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje pet CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL15/HCC-2, i CCL23/MPIF-1, i koji se ne veže na CCL2/MCP-1, koji sadrži kombinacije CDR nizova teških i lakih lanaca (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) odabranih iz skupine koja se sastoji od SEQ ID NO: 3/4/5/8/9/10 i 53/54/55/58/59/60, ili koji se natječe za vezanje na najmanje pet CC kemokina odabranih iz CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL15/HCC-2, i CCL23/MPIF-1, s antitijelima, ili fragmentom koji veže antigen koji sadrži kombinacije CDR slijeda teškog i lakog lanca odabranih iz skupine koja se sastoji od SEQ ID NO: 3/4/5/8/9/10 i 53/54/55/58/59/60.
The monoclonal antibody or antigen binding fragment of claim 9, which is produced by the hybridoma cell line producing MAb 3C12F, or by a subculture thereof; or which competitively blocks binding of an antibody produced by hybridoma cell line 3C12F, wherein said hybridoma cell line 3C12F was deposited on August 12, 2010 at the ATCC under the accession number PTA-11261. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 9, koji je proizveden od hibridne stanične linije koja proizvodi MAb 3C12F, ili njene subkulture; ili koji kompetitivno blokira vezanje protutijela kojeg proizvodi hibridna stanična linija 3C12F, naznačeno time, da je navedena hibridna stanična linija 3C12F pohranjena 12. kolovoza 2010. u ATCC pod pristupnim brojem PTA-11261.
The monoclonal antibody or antigen binding fragment thereof of claim 1 which binds to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL14/HCC-1, and CCL18/PARC, and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL14/HCC-1, i CCL18/PARC, i koji se ne vežu na CCL2/MCP-1.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL14/HCC-1, and CCL18/PARC, and which does not bind to CCL2/MCP-1, comprising a heavy and light chain CDR sequence combination (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) of SEQ ID NO: 23/24/25/28/29/30, or which competes for binding to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL4/HCC-1, and CCL18/PARC, with an antibody or antigen binding fragment comprising a heavy and light chain CDR sequence combination of SEQ ID NO: 23/24/25/28/29/30. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL14/HCC-1, i CCL18/PARC, a koji se ne vežu na CCL2/MCP-1, koji sadrži kombinaciju CDR slijedova teškog i lakog lanca (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) od SEQ ID NO: 23/24/25/28/29/30, ili koji se natječe za vezanje na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL4/HCC-1, i CCL18/PARC, s antitijelom ili fragmentom koji veže antigen koji sadrži kombinaciju CDR slijedova teškog i lakog lanca SEQ ID NO: 23/24/25/28/29/30.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, and CCL23/MPIF-1, and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da veže na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, i CCL23/MPIF-1, i koji se ne vežu na CCL2/MCP-1.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, and CCL23/MPIF-1, and which does not bind to CCL2/MCP-1, comprising a heavy and light chain CDR sequence combination (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) of SEQ ID NOS: 13/14/15/18/19/20, or which competes for binding to at least four CC chemokines selected from CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, and CCL23/MPIF-1, with an antibody or antigen binding fragment comprising a heavy and light chain CDR sequence combination of SEQ ID NOS: 13/14/15/18/19/20. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES, i CCL23/MPIF-1, i koji se ne veže na CCL2/MCP-1, koji sadrži kombinaciju CDR sekvence teškog i lakog lanca (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) od SEQ ID NOS: 13/14/15/18/19/20, ili koji se natječe za vezanje na najmanje četiri CC kemokina odabranih iz CCL3/MIP-1a, CCL4/MIP-1β, CCL5/RANTES i CCL23/MPIF-1, s antitijelima ili fragmentom koji veže antigen i koji sadrži kombinacije CDR slijeda teškog i lakog lanca SEQ ID NOS: 13/14/15/18/19/20.
The monoclonal antibody or antigen binding fragment of claim 15, which is produced by the hybridoma cell line producing MAb 7D12A, or by a subculture thereof; or which competitively blocks binding of an antibody produced by hybridoma cell line 7D 12A, wherein said hybridoma cell line 7D12A was deposited on August 12, 2010 at the ATCC under the accession number PTA-11259. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 15, koji je proizveden od hibridne stanične linije koja proizvodi Mab 7D12A, ili njene subkulture; ili koji kompetitivno blokira vezanje protutijela kojeg proizvodi hibridna stanična linija 7D 12A, naznačen time, da je spomenuta hibridna stanična linija 7D12A pohranjena 12. kolovoza 2010. u ATCC pod pristupnim brojem PTA-11259.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to three CC chemokines selected from the group consisting of CCL3/MIP-1a,CCL4/MIP-1β, and CCL5/RANTES and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na tri CC kemokina odabrana iz skupine koju čine CCL3/MIP-1a, CCL4/MIP-1β, i CCL5/RANTES i koji se ne vežu na CCL2/MCP-1.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to CCL3/MIP-1a, CCL4/MIP-1β, and CCL5/RANTES and which does not bind to CCL2/MCP-1, comprising a heavy and light chain CDR sequence combination (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) selected from the group consisting of SEQ ID NOS: 33/34/35/38/39/40 and 63/64/65/68/69/70, or which competes for binding to CCL3/MIP-1a, CCL4/MIP-1β, and CCL5/RANTES, with an antibody or antigen binding fragment comprising a heavy and light chain CDR sequence combination selected from the group consisting of SEQ ID NOS: 33/34/35/38/39/40 and 63/64/65/68/69/70. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na CCL3/MIP-1a, CCL4/MIP-1β, i CCL5/RANTES i koji se ne veže na CCL2/MCP-1, koji obuhvaća kombinacije CDR nizova teških i lakih lanaca (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) odabranih iz skupine koja se sastoji od SEQ ID NOS: 33/34/35/38/39/40 i 63/64/65/68/69/70, ili koji se natječe za vezanje na CCL3/MIP-1a, CCL4/MIP-1β, i CCL5/RANTES, s antitijelom ili fragmentom koji veže antigen i sadrži kombinacije CDR nizova teških i lakih lanaca odabrane iz skupine koju čine CEQ ID NO: 33/34/35/38/39/40 i 63/64/65/68/69/70.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least three CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1P, and CCL5/RANTES and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje tri CC kemokina odabrana iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1P, i CCL5/RANTES, a koji se ne veže to CCL2/MCP-1.
The monoclonal antibody or antigen binding fragment of any one of claims 9, 12, 15, 18 and 21, which binds to at least one antigenic determinant of CCL3/MIP-1a located within residues 11-15 (CCFSY), residues 17-24 (SRQIPQNF), residues 34-35 (QC), or residues 57-67 (EWVQKYVSDLE) of SEQ ID NO: 71; 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s bilo kojim od patentnih zahtjeva 9, 12, 15, 18 i 21, naznačeno time, da se veže na barem jednu antigensku determinantu CCL3/MIP-1a koja se nalazi unutar ostataka 11-15 (CCFSY), ostataka 17-24 (SRQIPQNF), ostataka 34-35 (QC), ili ostataka 57-67 (EWVQKYVSDLE) SEQ ID NO: 71;
which binds to at least one antigenic determinant of CCL5/RANTES located within residues 10-14 (CCFAY), residues 16-23 (ARPLPRAH), residues 33-34 (KC), or residues 56-66 (KWVREYINSLE) of SEQ ID NO: 73. 
koji se veže na barem jednu antigensku determinantu CCL5/RANTES koja se nalazi unutar ostataka 10-14 (CCFAY), ostataka 16-23 (ARPLPRAH), ostataka 33-34 (KC), odnosno ostataka 56-66 (KWVREYINSLE) od SEQ ID NO: 73.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least three chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1β, and CCL5/RANTES and which does not bind to CCL2/MCP-1 comprising a heavy and light chain CDR sequence combination (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) of SEQ ID NO: 43/44/45/48/49/50, or which competes for binding to CCL3/MIP-1a, CCL4/MIP-1β, and CCL5/RANTES, with an antibody or antigen binding fragment comprising a heavy and light chain CDR sequence combination of SEQ ID NO: 43/44/45/48/49/50. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje tri kemokinima odabrana iz skupine koju čine CCL3/MIP-1a, CCL4/MIP-1β, i CCL5/RANTES, a koji se ne veže na CCL2/MCP-1 i koji sadrže kombinacije CDR nizova teških i lakih lanaca (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) SEQ ID NO: 43/44/45/48/49/50, ili koji se natječe za vezivanje to CCL3/MIP-1a, CCL4/MIP-1β, i CCL5/RANTES, s antitijelom ili fragmentom koji veže antigen i sadrži kombinacije CDR nizova teških i lakih lanaca SEQ ID NO: 43/44/45/48/49/50.
A hybridoma cell line producing a monoclonal antibody according to claim 1. 
Hibrida stanična linija, naznačena time, da proizvodi monoklonsko antitijelo u skladu sa zahtjevom 1.
Monoclonal antibody of claim 1 or an antigen binding fragment thereof for use in treating a disease, disorder or condition mediated by one or more CC chemokines, wherein said disease, disorder, or condition is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, fibrotic disease, atherosclerosis, asthma, oncogenic diseases, inflammatory bowel diseases, atopic dermatitis, psoriasis, stroke, organ transplantation, COPD, glomerulonephritis, lupus nephritis, scleroderma, cirrhosis, Alzheimer's disease, CHF-ischemia, coronary restenosis, diabetic nephrophathy/neuropathy/retinopathy, osteoarthritis, periodontitis, yeast and viral infections, and dysregulation of pregnancy. 
Monoklonsko protutijelo u skladu s patentnim zahtjevom 1, ili njegov fragment koji veže antigen za upotrebu pri liječenju bolesti, poremećaja ili stanja uzrokovanih jednim ili više CC kemokina, naznačeno time, da je navedena bolest, poremećaj ili stanje odabrano iz skupine koja se sastoji od reumatoidnog artritisa, multiple skleroze, fibrozne bolesti, ateroskleroze, astme, onkogenih bolesti, upalne bolesti crijeva, atopičnog dermatitisa, psorijaze, moždanog udara, transplantacije organa, COPD, glomerulonefritisa, lupus nefritisa, skleroderma, ciroze, Alzheimer-ove bolesti, CHF-ishemije, koronarne restenoze, dijabetičke nefropatije / neuropatije / retinopatije, osteoartritisa, periodontitisa, infekcija uzrokovanih kvascem i virusima, te deregulacija trudnoće.
The coating composition according to any one of the preceding claims, wherein the hydrophilic groups have a number average molecular weight (Mn) in the range of 400-10,000 g/mol. 
Smjesa za premaz prema jednom od prethodno navedenih patentnih zahtjeva, naznačena time da hidrofilne skupine imaju prosječnu brojčanu molekulsku masu (Mn) u rasponu od 400-10.000 g/mol.
The coating composition according to any one of the preceding claims, wherein the hydrophilic-modified polysiloxane has a number average molecular weight (Mn) in the range of 500-50,000 g/mol. 
Smjesa za premaz prema jednom od prethodno navedenih patentnih zahtjeva, naznačena time da hidrofilno modificirani polisiloksan ima prosječnu brojčanu molekulsku masu (Mn) u rasponu od 500-50.000 g/mol.
The coating composition according to any one of the preceding claims, wherein the polysiloxane-based binder system constitutes at least 40 % by dry weight of the coating composition. 
Smjesa za premaz prema jednom od prethodno navedenih patentnih zahtjeva, naznačena time da sustav veziva na bazi polisiloksana čini najmanje 40% suhe mase smjese za premaz.
The coating composition according to claim 15, wherein the polysiloxane-based binder system constitutes 50-90 % by dry weight of the coating composition. 
Smjesa za premaz prema patentnom zahtjevu 15, naznačena time da sustav veziva na bazi polisiloksana čini 50-90% suhe mase smjese za premaz.
A top coat composition according to any one of the preceding claims which comprises: 
Smjesa za premaz prema jednom od prethodno navedenih patentnih zahtjeva, naznačena time da sadrži:
The coating composition according to any one of the preceding claims, wherein the polysiloxane based binder is a functional organopolysiloxane with terminal and/or pendant functionality, said functionality either being hydrolysable groups or silanol groups. 
Smjesa za premaz prema jednom od prethodno navedenih zahtjeva, naznačena time da je vezivo na bazi polisiloksana funkcionalni organopolisiloksan s terminalnom i/ili postojećom funkcionalnošću, pri čemu je navedena funkcionalnost hidrolizirajuća skupina ili silanolna skupina.
The coating composition according to any one of the preceding claims, wherein the polysiloxane-based binder system comprises (i) a binder and (ii) a cross-linking agent, wherein the binder (i) constitutes 20-90 % by dry weight of the coating composition, and is a curable diorganopolysiloxane represented by general formula (1): wherein 
Smjesa za premaz prema jednom od prethodno navedenih patentnih zahtjeva, naznačena time da vezivni sustav na bazi polisiloksana sadrži (i), vezivo te (ii) sredstvo za poprečno povezivanje, pri čemu vezivo (i) čini 20-90% suhe mase smjese za premaz, te je diorganopolisiloksan koji se upotrebljava u liječenju i koji je predstavljen općom formulom (1):
The coating composition according to any one of the claims 19-20, wherein the organopolysiloxane has terminal groups of epoxy or amine and pendant hydrolysable groups with alkoxy functionality. 
Smjesa za premaz prema bilo kojem od patentnih zahtjeva 19-20, naznačena time da organopolisiloksan ima terminalne ili epoksi ili amino skupine, kao i postojeće hidrolizirajuće skupine s alkoksi funkcionalnošću.
The coating composition according to any one of the claims 19-21, wherein said hydrolysable groups are selected from alkoxy groups and ketoxime groups. 
Smjesa za premaz prema bilo kojem od patentnih zahtjeva 19-21, naznačena time da je navedena hidrolizirajuća skupina odabrana iz alkoksi skupine ili ketoksim skupine.
The coating composition according to any one of the preceding claims, wherein the binder system comprises a cross-linker selected from tetraethoxysilane; vinyltris(methylethyloximo)silane; methyltris(methylethyloximo)silane; vinyltrimethoxysilane; methyltrimethoxysilane and vinyltriisopropenoxysilane; and hydrolysis-condensation products of the same. 
Smjesa za premaz prema jednom od prethodno navedenih patentnih zahtjeva, naznačena time da sustav veziva sadrži sredstvo za poprečno povezivanje odabrano iz tetraetoksisilana; viniltris(metiletiloksimo)silana; metiltris(metiletiloksimo)silana; viniltrimetoksisilana; metiltrimetoksisilana i viniltriizopropenoksisilana; te njihovih proizvoda nastalih hidrolizom i kondenzacijom.
The coating composition according to any one of the preceding claims, wherein hydrophilic character of the one or more hydrophilic-modified polysiloxanes is obtained by addition of oligomeric or polymeric groups selected from amides, acids, alcohols, ketones, aldehydes, amines, esters, ethers, and imides, including copolymers thereof. 
Smjesa za premaz prema bilo kojem od prethodno navedenih patentnih zahtjeva, naznačena time da se hidrofilni karakter jednog ili više hidrofilno modificiranih polisiloksana dobiva dodavanjem oligomernih ili polimernih skupina odabranih iz amida, kiselina, alkohola, ketona, aldehida, amina, estera, etera i imida, uključujući njihove kopolimere.
The coating composition according to any one of the preceding claims, wherein the hydrophilic-modified polysiloxane is a poly(oxyalkylene)-modified polysiloxane. 
Smjesa za premaz prema bilo kojem od prethodno navedenih patentnih zahtjeva, naznačena time da je hidrofilno modificirani polisiloksan zapravo poli(oksialkilen)-modificirani polisiloksan.
The coating composition according to claim 26, wherein the poly(oxyalkylene)-modified polysiloxane is a polysiloxane having grafted thereto poly(oxyalkylene) chains. 
Smjesa za premaz prema patentnom zahtjevu 26, naznačena time da je poli(oksialkilen)-modificirani polisiloksan zapravo polisiloksan koji sadrži poli(oksialkilenske) lance.
An in vitro method of inducing a cytotoxic T cell by contacting a T cell with a peptide of any one of claims 1 to 5. 
Postupak induciranja citotoksične T-stanice in vitro, naznačen time što se sastoji u stavljanju u kontakt T-stanice s peptidom u skladu s bilo kojim od patentnih zahtjeva 1 i 5.
mixing the antigen-presenting cell of step (i) with a CD8+ T cell and co-culturing. 
miješanju predočne stanice iz koraka (i) s CD8+ T-stanicom i suuzgoja.
The pharmaceutical composition of claim 6, or the peptide or polynucleotide of claim 15, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, endometriosis, esophageal cancer, gastric cancer, diffused type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 6, ili peptid ili polinukleotid u skladu s patentnim zahtjevom 15, naznačen time što se rak bira iz skupine koju čine rak mokraćnog mjehura, rak dojke, rak vrata maternice, kolangiocelularni karcinom, CML, kolorektalni rak, endometrioza, rak jednjaka, rak želuca, rak želuca difuznog tipa, rak jetre, NSCLC, limfom, osteosarkom, rak jajnika, gušterače rak, rak prostate, bubrežni karcinom, SCLC, tumor mekog tkiva i tumor na testisima.
contacting a peptide consisting of the candidate sequence selected in step (ii) with antigen presenting cells; 
stavljanja u kontakt peptida koji se sastoji od slijeda kandidata odabranog u koraku (ii) s predočnim stanicama;
identifying the peptide of which cytotoxic T cell inducibility is same to or higher than a peptide consisting of the original amino acid sequence. 
identificiranja peptida čije je sposobnost induciranja citotoksične T-stanice ista kao ili veća nego kod peptida koji ima izvorni aminokiselinski slijed.